Cytosorbents (NASDAQ:CTSO) Posts Quarterly Earnings Results

Cytosorbents (NASDAQ:CTSO) announced its quarterly earnings data on Thursday. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03), Zacks reports. The company had revenue of $9.63 million for the quarter, compared to the consensus estimate of $9.38 million. Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.

Here are the key takeaways from Cytosorbents’ conference call:

• Profitability and cash-burn trends improved: Second-quarter gross margin rose to 73%, adjusted EBITDA loss improved 38% year over year, and operating cash burn fell to approximately $200,000 excluding restructuring payments. Management reiterated its expectation of reaching operating cash-flow breakeven in the second half of 2026.
• Revenue remained essentially flat at $9.6 million: Distributor and strategic-partner revenue increased 16% year over year and direct sales outside Germany rose 9%, offset by continued weakness in Germany and Middle East disruptions. The company plans to add three to five German sales representatives through early 2027.
• DrugSorb-ATR still faces regulatory uncertainty: The FDA previously denied the company’s de novo application because the pivotal STAR-T trial missed its primary endpoint, although management said a new clinical trial is not required. Cytosorbents plans to submit additional mechanistic data and real-world evidence, with separate FDA discussions planned for the ticagrelor and DOAC indications.
• Management highlighted favorable DrugSorb-ATR secondary analyses: In the CABG per-protocol population, the severe-bleeding endpoint achieved a statistically significant win ratio of 1.59, while a composite of severe bleeding or more than one liter of chest-tube blood loss showed a reported 58% relative risk reduction. These analyses may support a renewed FDA submission, though they do not eliminate the prior primary-endpoint miss.
• HemoDefend-BGA represents longer-term strategic optionality rather than current revenue: The universal-plasma technology has completed development and received constructive FDA feedback on a potential clinical pathway, but Cytosorbents does not plan to fund clinical trials from its current resources. Progress depends on government funding, partnerships, licensing, or another strategic transaction.

Cytosorbents Stock Performance

NASDAQ:CTSO traded down $0.04 during mid-day trading on Friday, reaching $0.36. 96,364 shares of the company’s stock were exchanged, compared to its average volume of 61,883. Cytosorbents has a one year low of $0.35 and a one year high of $1.22. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The business’s fifty day simple moving average is $0.40 and its two-hundred day simple moving average is $0.55. The firm has a market capitalization of $22.62 million, a PE ratio of -1.24 and a beta of 1.39.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cytosorbents has a consensus rating of “Hold” and an average target price of $5.38.

Insider Transactions at Cytosorbents

In other Cytosorbents news, CEO Phillip P. Chan bought 251,136 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were purchased at an average price of $0.40 per share, for a total transaction of $100,454.40. Following the transaction, the chief executive officer directly owned 1,734,099 shares in the company, valued at approximately $693,639.60. This trade represents a 16.93% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cytosorbents

Large investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. acquired a new stake in Cytosorbents in the third quarter valued at about $161,000. Avenir Corp increased its position in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after purchasing an additional 147,261 shares in the last quarter. Vanguard Group Inc. increased its position in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares during the last quarter. Finally, Citadel Advisors LLC lifted its stake in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.